Fundraising FoxElucid Bioimaging
Boston, US · 5 known investors
Find your way into Elucid Bioimaging
Sign up to see every warm intro you have to Elucid Bioimaging
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Elucid Bioimaging team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Elucid develops artificial intelligence technology that analyzes CT images to identify hidden features of cardiovascular risk and guide personalized treatment of coronary artery disease. The platform enables physicians to create detailed disease maps and deliver personalized care based on individual patient anatomy.
Founders & leadership
Board
Investors · 5
How we know: Angel Physicians Fund's portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Funding
SEC filings, press & company announcements$225.4M disclosed across 4 rounds · 2023–2026
▶$36.5MraisedOct 2025 · 9 investors · BiotechnologyRule 506(b)
- Evan MelroseDirector
- Michael LeshDirector
- Blake RichardsExecutive Officer
- Richard KuntzDirector
- Rajesh PandaDirector
- Kelly HuangExecutive Officer, Director
- Shamiram FeinglassDirector
- Scott HuennekensDirector
- Offering amount
- $80M
- Amount sold
- $36.5M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$79MraisedNov 2023 · 13 investors · BiotechnologyRule 506(b)
- Robert BraunDirector
- Scott HuennekensExecutive Officer, Director
- Michael LeshDirector
- Blake RichardsExecutive Officer, Director
- Evan MelroseDirector
- Offering amount
- $79M
- Amount sold
- $79M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Elucid Bioimaging do?
- Elucid develops artificial intelligence technology that analyzes CT images to identify hidden features of cardiovascular risk and guide personalized treatment of coronary artery disease. The platform enables physicians to create detailed disease maps and deliver personalized care based on individual patient anatomy.
- Who are Elucid Bioimaging's investors?
- Elucid Bioimaging's investors include Angel Physicians Fund, Aphelion Capital, BlueStone Venture Partners, IAG Capital Partners, MedTex Ventures LLC.
- How much funding has Elucid Bioimaging raised?
- Elucid Bioimaging has disclosed $225.4M raised across 4 rounds.
- Where is Elucid Bioimaging headquartered?
- Elucid Bioimaging is headquartered in Boston, US.